Fountain Medical Development, a clinical stage contract research organization (CRO) dedicated to offering high-quality one-stop-shop services to pharmaceutical & medical device clients, announces the appointment of Ling Zhen as the Co-Chairman of the Board of Directors & CEO.

Ling possesses over 25 years of professional experience in the CRO & life science industries, both in China and the US. Most recently, he has served as a Partner at Draper Dragon Venture Group, where he focused on biopharmaceutical & medical technology investments. Prior to this, he has also spent over 12 years at IQVIA, where he served as a global Senior Vice President & the General Manager of Greater China. During this period, he helped drive expansion & transformation of IQVIA China into a market leader through innovative solutions & strategic growth in the region.

Prior to IQVIA and Quintiles, Ling has also worked in business development, portfolio management & strategic consulting at world-leading companies such as Eli Lilly, GlaxoSmithKline and Ernst &Young in the US. He holds a Master of Business Administration (MBA) degree from the Kelley School of Business in Indiana

His hands-on experience and strategic insight related to the CRO sector makes him the ideal leader to transform Fountain Medical into a China-centered global full-service leading CRO

University and a Juris Doctor (JD) degree from the Law School of North Carolina Central University, and is a licensed attorney in the US.

Commenting on this appointment, Dr. Dan Zhang, Co-Chairman & Co-Founder, Fountain Medical Development, says, “With the appointment of Mr. Ling Zhen as the Co-Chairman and CEO, Fountain Medical will be able to speed up its global expansion and strategic buildup, allowing us to better serve our existing and future clientele. His hands-on experience and strategic insight related to the CRO sector makes him the ideal leader to transform Fountain Medical into a China-centered, global full-service leading CRO.”

“I feel very privileged to join Fountain Medical during this exciting time, where drug development and clinical research are undergoing transformational changes across China and rest of the world,” avers Ling, Co-Chairman & CEO, Fountain Medical Development. “I look forward to working closely with Fountain Medical's management team and shareholders, and developing a high-caliber team that delivers high-quality services, to help our customers accelerate the development of truly innovative therapies around the world,” he concludes.